BBS-Bioactive Bone Substitutes Oyj (BONEH) - Cash Flow Conversion Efficiency

Latest as of June 2024: -0.416x

Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) has a cash flow conversion efficiency ratio of -0.416x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.58 Million ≈ $-1.84 Million USD) by net assets (€3.79 Million ≈ $4.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BBS-Bioactive Bone Substitutes Oyj net asset quality index to measure how much of total assets are equity-financed.

BBS-Bioactive Bone Substitutes Oyj - Cash Flow Conversion Efficiency Trend (2015–2023)

This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of BBS-Bioactive Bone Substitutes Oyj to evaluate the quality of earnings relative to operating cash generation.

BBS-Bioactive Bone Substitutes Oyj Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BBS-Bioactive Bone Substitutes Oyj ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CQS Natural Resources Growth and Income plc LSE:CYN	-0.001x
DevvStream Corp. Common Stock NASDAQ:DEVS	0.150x
Yida China Holdings Ltd STU:YC2	N/A
INCUVO S.A. ZY -50 F:68X	0.135x
Prostatype Genomics AB ST:PROGEN	-0.234x
WILDCAT PRETR.LS -000028 F:8Y6	N/A
TELES Informationstechnologien AG XETRA:TLIK	N/A
Scheerders van Kerchove's Verenigde fabrieken nv BR:SCHD	0.091x

Annual Cash Flow Conversion Efficiency for BBS-Bioactive Bone Substitutes Oyj (2015–2023)

The table below shows the annual cash flow conversion efficiency of BBS-Bioactive Bone Substitutes Oyj from 2015 to 2023. For the full company profile with market capitalisation and key ratios, see BBS-Bioactive Bone Substitutes Oyj stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	€5.11 Million ≈ $5.97 Million	€-2.92 Million ≈ $-3.42 Million	-0.572x	+13.21%
2022-12-31	€4.27 Million ≈ $4.99 Million	€-2.82 Million ≈ $-3.29 Million	-0.659x	+4.93%
2021-12-31	€3.63 Million ≈ $4.25 Million	€-2.52 Million ≈ $-2.95 Million	-0.693x	-74.58%
2020-12-31	€6.09 Million ≈ $7.12 Million	€-2.42 Million ≈ $-2.83 Million	-0.397x	+15.30%
2019-12-31	€3.08 Million ≈ $3.60 Million	€-1.44 Million ≈ $-1.69 Million	-0.469x	-21.77%
2018-12-31	€4.42 Million ≈ $5.16 Million	€-1.70 Million ≈ $-1.99 Million	-0.385x	+61.34%
2017-12-31	€1.08 Million ≈ $1.26 Million	€-1.08 Million ≈ $-1.26 Million	-0.996x	-738.64%
2016-12-31	€4.60 Million ≈ $5.37 Million	€-546.00K ≈ $-638.33K	-0.119x	-23.33%
2015-12-31	€4.46 Million ≈ $5.22 Million	€-430.00K ≈ $-502.72K	-0.096x	--

About BBS-Bioactive Bone Substitutes Oyj

HE:BONEH Finland Medical Devices

Market Cap

$1.76 Million

€1.50 Million EUR

Market Cap Rank

#30280 Global

#150 in Finland

Share Price

€0.05

Change (1 day)

+0.00%

52-Week Range

€0.05 - €0.05

All Time High

€9.68